Job Market Relief, Biogen’s Big Bet, and Stop Trying to Beat the Market! 1/6/23

Stocks rallying after wages in December grew at a slower than expected rate. We dig into what it means for the Fed and your money. The FDA expected to decide on Biogen’s second Alzheimer’s treatment, Jefferies’ analyst Michael Yee tells us what makes this drug different than its maligned first drug Aduhelm. Plus, “A Random Walk Down Wall Street” 50 years later. Wall St. legend Burt Malkiel makes his case for passive investing and why investors shouldn’t trust historic returns…especially now.